Search Results - "Hussein, Maen"

Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153 by Waterhouse, David M, Garon, Edward B, Chandler, Jason, McCleod, Michael, Hussein, Maen, Jotte, Robert, Horn, Leora, Daniel, Davey B, Keogh, George, Creelan, Ben, Einhorn, Lawrence H, Baker, Justin, Kasbari, Samer, Nikolinakos, Petros, Babu, Sunil, Couture, Felix, Leighl, Natasha B, Reynolds, Craig, Blumenschein, Jr, George, Gunuganti, Vijay, Li, Ang, Aanur, Nivedita, Spigel, David R

“…Limited data exist on the optimal duration of immunotherapy, including for non-small-cell lung cancer (NSCLC). We present an exploratory analysis of CheckMate…”
Get full text

Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study by Hart, Lowell L., Ferrarotto, Renata, Andric, Zoran G., Beck, J. Thaddeus, Subramanian, Janakiraman, Radosavljevic, Davorin Z., Zaric, Bojan, Hanna, Wahid T., Aljumaily, Raid, Owonikoko, Taofeek K., Verhoeven, Didier, Xiao, Jie, Morris, Shannon R., Antal, Joyce M., Hussein, Maen A.

“…Introduction Multilineage myelosuppression is an acute toxicity of cytotoxic chemotherapy, resulting in serious complications and dose modifications. Current…”
Get full text

Monoclonal gammopathy of thrombotic/thrombocytopenic significance by Kanack, Adam J., Schaefer, Jordan K., Sridharan, Meera, Splinter, Noah P., Kohlhagen, Mindy C., Singh, Bandana, De Lorenzo, Silvana B., Mauch, Emily E., Hussein, Maen A., Shaikh, Marwan, Kumar, Shaji, Wen, Renren, Wang, Demin, Murray, David, Padmanabhan, Anand

Get full text

PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer by Yu, Hui, Batenchuk, Cory, Badzio, Andrzej, Boyle, Theresa A, Czapiewski, Piotr, Chan, Daniel C, Lu, Xian, Gao, Dexiang, Ellison, Kim, Kowalewski, Ashley A, Rivard, Christopher J, Dziadziuszko, Rafal, Zhou, Caicun, Hussein, Maen, Richards, Donald, Wilks, Sharon, Monte, Marc, Edenfield, William, Goldschmidt, Jerome, Page, Ray, Ulrich, Brian, Waterhouse, David, Close, Sandra, Jassem, Jacek, Kulig, Kimary, Hirsch, Fred R

“…Therapeutic antibodies to immune checkpoints show promising results. Programmed death-ligand 1 (PD-L1), an immune checkpoint ligand, blocks the cancer immunity…”
Get more information

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab as first-line treatment for metastatic non-small cell lung cancer with high levels of programmed death-ligand 1: a randomized, double-blind phase 2 study by Tokito, Takaaki, Kolesnik, Oleksii, Sørensen, Jens, Artac, Mehmet, Quintela, Martín Lázaro, Lee, Jong-Seok, Hussein, Maen, Pless, Miklos, Paz-Ares, Luis, Leopold, Lance, Daniel, Jeannie, Munteanu, Mihaela, Samkari, Ayman, Xu, Lu, Butts, Charles

“…Pembrolizumab is a first-line therapy for certain patients with advanced/metastatic non-small cell lung cancer (NSCLC). Combining pembrolizumab with other…”
Get full text

IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC by Jotte, Robert M., Cappuzzo, Federico, Vynnychenko, Ihor, Stroyakovskiy, Daniil, Rodriguez Abreu, Delvys, Hussein, Maen A., Soo, Ross A., Conter, Henry Jacob, Kozuki, Toshiyuki, Silva, Carlos, Graupner, Vilma, Sun, Shawn, Lin, Ray S, Kelsch, Claudia, Kowanetz, Marcin, Hoang, Tien, Sandler, Alan, Socinski, Mark A.

“…Abstract only LBA9000 Background: Atezolizumab (atezo; anti–PD-L1) demonstrated OS benefit vs docetaxel in 2L+ NSCLC regardless of PD-L1 status or tumor…”
Get full text

Approach to Anemia by Hussein, Maen, MD, Haddad, Rami Y., MD, FACP

Get full text

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial by West, Howard, McCleod, Michael, Hussein, Maen, Morabito, Alessandro, Rittmeyer, Achim, Conter, Henry J, Kopp, Hans-Georg, Daniel, Davey, McCune, Steven, Mekhail, Tarek, Zer, Alona, Reinmuth, Niels, Sadiq, Ahad, Sandler, Alan, Lin, Wei, Ochi Lohmann, Tania, Archer, Venice, Wang, Lijia, Kowanetz, Marcin, Cappuzzo, Federico

“…Atezolizumab (a monoclonal antibody against PD-L1), which restores anticancer immunity, improved overall survival in patients with previously treated…”
Get full text

Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study by Johnson, Melissa L, Cho, Byoung Chul, Luft, Alexander, Alatorre-Alexander, Jorge, Geater, Sarayut Lucien, Laktionov, Konstantin, Kim, Sang-We, Ursol, Grygorii, Hussein, Maen, Lim, Farah Louise, Yang, Cheng-Ta, Araujo, Luiz Henrique, Saito, Haruhiro, Reinmuth, Niels, Shi, Xiaojin, Poole, Lynne, Peters, Solange, Garon, Edward B, Mok, Tony

“…The open-label, phase III POSEIDON study evaluated tremelimumab plus durvalumab and chemotherapy (T + D + CT) and durvalumab plus chemotherapy (D + CT) versus…”
Get full text

Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial by Jotte, Robert, Cappuzzo, Federico, Vynnychenko, Ihor, Stroyakovskiy, Daniil, Rodríguez-Abreu, Delvys, Hussein, Maen, Soo, Ross, Conter, Henry J, Kozuki, Toshiyuki, Huang, Kuan-Chieh, Graupner, Vilma, Sun, Shawn W, Hoang, Tien, Jessop, Helen, McCleland, Mark, Ballinger, Marcus, Sandler, Alan, Socinski, Mark A

“…Cytotoxic agents have immunomodulatory effects, providing a rationale for combining atezolizumab (anti-programmed death-ligand 1 [anti-PD-L1]) with…”
Get more information

Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study by Cho, Byoung Chul, Abreu, Delvys Rodriguez, Hussein, Maen, Cobo, Manuel, Patel, Anjan J, Secen, Nevena, Lee, Ki Hyeong, Massuti, Bartomeu, Hiret, Sandrine, Yang, James Chih Hsin, Barlesi, Fabrice, Lee, Dae Ho, Ares, Luis Paz, Hsieh, Robert W, Patil, Namrata S, Twomey, Patrick, Yang, Xiaoying, Meng, Raymond, Johnson, Melissa L

“…Targeted inhibition of the PD-L1–PD-1 pathway might be further amplified through combination of PD-1 or PD-L1 inhibitors with novel anti-TIGIT inhibitory…”
Get full text

MyTACTIC: Afficacy and safety of atezolizumab (atezo) + chemotherapy (chemo) in patients (pts) with advanced unresectable/metastatic solid tumors with high tumor mutational burden (TMB-H) or high microsatellite instability (MSI-H)/deficient mismatch repair (dMMR) by Spigel, David R., Hussein, Maen A., Zuniga, Richard, Mahadevan, Daruka, Winn, Robert, Darbonne, Walter C., Yoo, Bongin, Kim, Young, Whitehead, Zach, Vanderwalde, Ari M.

“…2612 Background: MyTACTIC (NCT04632992) is a phase II, non-randomized, multi-arm basket study evaluating targeted therapies as single agents or combinations in…”
Get full text

Ezabenlimab (BI 754091), an anti-PD-1 antibody, in combination with BI 836880, a VEGF/Ang2-blocking nanobody, in patients (pts) with advanced colorectal cancer (CRC) by Ulahannan, Susanna Varkey, Percent, Ivor John, Arrowsmith, Edward, Hussein, Maen A., Bhanderi, Viralkumar K., Hamm, John, Durm, Greg Andrew, Erzen, Damijan, Mohanty, Prasant, Spigel, David R.

“…Abstract only 98 Background: Anti-PD-1 antibodies may have synergistic effects with other immunomodulatory or targeted agents. This open-label, Phase II…”
Get full text

Real-world practice patterns and barriers to quality care in acute myeloid leukemia (AML) by Hussein, Maen A., Patel, Taral, Ellipeddi, Pavani, Farris, Breanne, Crawford, Rebecca R, Carter, Jeffrey D., Sapir, Tamar, Wang, Eunice S.

“…Abstract only e19172 Background: For AML patients who are ineligible for intensive induction, novel therapies have greatly improved treatment options, though…”
Get full text

Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I) (1300) by Lee, Elizabeth, Rodon, Jordi, Demeure, Michael, Deming, Dustin, Federman, Noah, McKean, Meredith, Spira, Alexander, Kwiatkowski, David, Hussein, Maen, Gordon, Erlinda, Crockett, David, Ganjoo, Kristen, Schulte, Brian, Cranmer, Lee, Schmid, Anita, Navarro, Willis, Itri, Loretta, Iyer, Gopa

Get full text

Practice transformation at scale through a microsystems quality improvement (QI) approach by Gordan, Lucio N., Chaudhry, Basit Iqbal, Hussein, Maen A., Connor, Nora, Yue, Andrew, Diaz, Michael, Strickland, T. R., Tran, Lisa, Walcker, Nathan

“…Abstract only e18667 Background: How oncology providers should implement practice transformation for value-based care is unclear, particularly at scale…”
Get full text

Platform trial of BI 754091, an anti-PD-1 antibody, in patients with previously treated advanced solid tumors: Combination with BI 836880, a VEGF/Ang2-blocking nanobody by Hussein, Maen A., Bendell, Johanna C., Arkenau, Hendrik-Tobias, Chu, Quincy S., Hansen, Aaron Richard, Erzen, Damijan, Sun, Zhichao, Lucarelli, Anthony, Percent, Ivor John

“…Abstract only TPS152 Background: Combining anti-programmed cell death protein 1 (PD-1) antibodies with other immuno-modulatory or targeted therapies may…”
Get full text

Real-world practice patterns in follicular lymphoma (FL) care at community oncology centers by Barr, Paul M., Patel, Taral, Dela Cruz, Servillano E., Hussein, Maen A., Castine, Michael J., Farris, Breanne Y, Crawford, Rebecca R, Carter, Jeffrey D., Sapir, Tamar

“…Abstract only 231 Background: Though FL generally has good outcomes, patients with high risk FL have poorer outcomes; proper risk stratification for early…”
Get full text

Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON) by Garon, Edward B, Cho, Byoung Chul, Luft, Alexander, Alatorre-Alexander, Jorge, Geater, Sarayut Lucien, Kim, Sang-We, Ursol, Grygorii, Hussein, Maen, Lim, Farah Louise, Yang, Cheng-Ta, Araujo, Luiz Henrique, Saito, Haruhiro, Reinmuth, Niels, Medic, Nenad, Mann, Helen, Shi, Xiaojin, Peters, Solange, Mok, Tony, Johnson, Melissa

“…In the phase 3 POSEIDON study, first-line tremelimumab plus durvalumab and chemotherapy significantly improved overall survival and progression-free survival…”
Get full text

Phase 2, multicenter, open-label basket trial of nab -sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I) by Iyer, Gopa, Deming, Dustin A., Demeure, Michael J., Federman, Noah, McKean, Meredith, Lee, Elizabeth Katherine, Spira, Alexander I., Kwiatkowski, David J., Hussein, Maen A., Gordon, Erlinda Maria, Crockett, David G., Ganjoo, Kristen N., Schulte, Brian, Cranmer, Lee D., Ding, Li, Schmid, Anita N., Navarro, Willis H., Rodon Ahnert, Jordi

“…TPS3168 Background: nab-Sirolimus is a novel albumin-bound mTOR inhibitor (mTORi) approved in the US for adult patients with malignant PEComa. In an…”
Get full text